Open AccessBroncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa
Author(s) -
Qinglin Meng,
P Li,
Y Li,
J Chen,
L Wang,
Lin He,
Jianteng Xie,
Xiang Gao
Publication year - 2019
Publication title -
rhinology (amsterdam. online)/rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.275
H-Index - 57
eISSN - 1996-8604
pISSN - 0300-0729
DOI - 10.4193/rhin19.161
Subject(s) - medicine , rhinorrhea , placebo , mucous membrane of nose , nasal lavage , gastroenterology , nasal administration , respiratory tract , nasal congestion , loratadine , respiratory system , allergy , nose , immunology , surgery , pathology , alternative medicine
Probiotics are mainly distributed in the mucosal system and have the ability to enhance mucosal barrier function and regulate immune responses. Broncho-Vaxom (BV), as a probiotic, has been applied to patients suffering from respiratory tract infections, but its potential effectiveness in allergic rhinitis (AR) has not been evaluated in human. This study aimed to investigate the clinical efficacy of BV in patients with persistent AR and to elucidate the underlying cellular mechanisms.